Share this article on:

Early Markers of HIV-1 Disease Progression in a Prospective Cohort of Seroconverters in Bangkok, Thailand: Implications for Vaccine Trials

Buchacz, Kate PhD, MPH*†; Hu, Dale J. MD, MPH; Vanichseni, Suphak MD, MPH; Mock, Philip A. MAppStats§; Chaowanachan, Thanyanan MSc§; Srisuwanvilai, La-ong MSc; Gvetadze, Roman MD, MSPH; van Griensven, Frits PhD, MPH†§; Tappero, Jordan W. MD, MPH†§; Kitayaporn, Dwip MD, DrPH; Kaewkungwal, Jaranit PhD; Choopanya, Kachit MD, MPH; Mastro, Timothy D. MD

JAIDS Journal of Acquired Immune Deficiency Syndromes: July 1st, 2004 - Volume 36 - Issue 3 - p 853-860
Epidemiology and Social Science

Background: Some candidate HIV-1 vaccines may not prevent HIV-1 infection but may alter the course of disease. Surrogate endpoints based on early laboratory makers in HIV-1–infected persons who are antiretroviral therapy (ART)–naive will be useful for evaluating vaccine efficacy in slowing disease progression (VEp). We examined pretreatment HIV-1 viral loads and CD4 cell counts in recent HIV-1 seroconverters to inform selection of these endpoints.

Methods: We studied 130 newly HIV-1–infected injection drug users identified from a prospective cohort of initially uninfected persons in Bangkok during 1995 through 1998. We analyzed trends in HIV-1 viral loads and CD4 cell counts as well as progression to the surrogate endpoint, defined as 2 consecutive CD4 cell counts of fewer than 350 cells/mm3, during 24 months after the first HIV-1 seropositive (FP) visit.

Results: Median HIV-1 RNA copies/mL with interquartile ranges were 43,693 (14,320–94,767) at the FP visit, 46,924 (16,273–104,314) at 6 months, 28,446 (11,292–54,325) at 12 months, and 18,080 (8713–54,059) at 18 months. HIV-1 viral loads at the FP visit and at 18 months were positively correlated (r = 0.53, P < 0.0001). Of 130 participants, 12% reached the surrogate endpoint by 6 months, 16% by 12 months, and 27% by 18 months. In Cox regression analyses, HIV-1 viral loads of more than 50,000 copies/mL at the FP visit (hazard ratio [HR] = 2.3, 95% confidence interval [CI]: 1.1–4.8) and first CD4 cell count of 500 or fewer cells/mm3 (HR = 7.6, 95% CI: 3.2–17.6) were independently associated with faster progression to the surrogate endpoint.

Conclusions: Participants with high HIV-1 RNA levels and low CD4 cell counts close to the time of seroconversion were more likely to experience early immunologic progression. Approximately one quarter of seroconverters reached the surrogate immunologic endpoint within 18 months of their FP visit and before starting ART, suggesting the utility of this endpoint for analyses of VEp in some ongoing and planned HIV-1 vaccine efficacy trials.

From the *Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA; †Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA; ‡Bangkok Metropolitan Administration, Bangkok, Thailand; §Thailand Ministry of Public Health–US Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand; and ‖Mahidol University, Bangkok, Thailand.

Received for publication August 5, 2003; accepted January 5, 2004.

Financially supported by the US Centers for Disease Control and Prevention as part of a research collaboration with the Bangkok Metropolitan Administration and the Ministry of Public Health of Thailand.

Reprints: Kate Buchacz, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop E-45, Atlanta, GA 30333 (e-mail: acu7@cdc.gov).

© 2004 Lippincott Williams & Wilkins, Inc.